Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study.
Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study.
复制标题
DOI：
10.1136/bmjno-2021-000214
复制
发表时间：
2022
影响因子：
2.7
通讯作者：
Antoniades CA
中科院分区：
文献类型：
--
作者：
Pereira MF;Buchanan T;Höglinger GU;Bogdanovic M;Tofaris G;Prangnell S;Sarangmat N;FitzGerald JJ;Antoniades CA
进行性核上性麻痹（PSP）是一种罕见的神经退行性疾病，其特征是一系列运动和认知症状。关于这些症状随时间的纵向变化知之甚少。此外，临床量表检测PSP早期变化的有效性仍然是一个有争议的问题。我们的目标是使用2年内多个间隔紧密的随访时间点来确定PSP特征的纵向变化。 方法对28名正常对照者和28名PSP患者进行前瞻性研究，平均发病时间为1.9年，每3个月进行一次，持续24个月。在每个随访时间点使用多个临床量表计算评分较基线的变化，以确定运动和认知症状的纵向进展。蒙特利尔认知评估，但不是简易精神状态检查，检测到基线认知下降。两种量表均显示对总体认知症状的临床变化的纵向敏感性较差。相反，运动障碍协会统一帕金森病评定量表-第三部分和PSP评定量表（PSPRS）在疾病发作后不到2年内可靠地检测到运动功能下降。“步态/中线”PSPRS分项评分随时间持续下降，最早的变化在基线评估后6个月观察到。虽然仍然需要更好的认知筛查工具来监测PSP的认知下降，但临床评定量表始终可以捕获运动功能下降。这些结果支持在PSP早期阶段的纵向研究中纳入多个随访时间点。
Progressive supranuclear palsy (PSP) is a rare neurodegenerative condition characterised by a range of motor and cognitive symptoms. Very little is known about the longitudinal change in these symptoms over time. Moreover, the effectiveness of clinical scales to detect early changes in PSP is still a matter of debate. We aimed to determine longitudinal changes in PSP features using multiple closely spaced follow-up time points over a period of 2 years. Methods 28 healthy control and 28 PSP participants, with average time since onset of symptoms of 1.9 years, were prospectively studied every 3 months for up to 24 months. Changes from baseline scores were calculated at each follow-up time point using multiple clinical scales to identify longitudinal progression of motor and cognitive symptoms. The Montreal Cognitive Assessment, but not the Mini-Mental State Examination, detected cognitive decline at baseline. Both scales revealed poor longitudinal sensitivity to clinical change in global cognitive symptoms. Conversely, the Movement Disorders Society Unified Parkinson’s disease Rating Scale – part III and the PSP Rating Scale (PSPRS) reliably detected motor decline less than 2 years after disease onset. The ‘Gait/Midline’ PSPRS subscore consistently declined over time, with the earliest change being observed 6 months after baseline assessment. While better cognitive screening tools are still needed to monitor cognitive decline in PSP, motor decline is consistently captured by clinical rating scales. These results support the inclusion of multiple follow-up time points in longitudinal studies in the early stages of PSP.
登录
查看更多内容
影响因子：
48
作者：
Boxer, Adam L.;Lang, Anthony E.;Grossman, Murray;Knopman, David S.;Miller, Bruce L.;Schneider, Lon S.;Doody, Rachelle S.;Lees, Andrew;Golbe, Lawrence I.;Williams, David R.;Corvol, Jean-Cristophe;Ludolph, Albert;Burn, David;Lorenzl, Stefan;Litvan, Irene;Roberson, Erik D.;Hoeglinger, Guenter U.;Koestler, Mary;Jack, Clifford R., Jr.;Van Deerlin, Viviana;Randolph, Christopher;Lobach, Iryna V.;Heuer, Hilary W.;Gozes, Illana;Parker, Lesley;Whitaker, Steve;Hirman, Joe;Stewart, Alistair J.;Gold, Michael;Morimoto, Bruce H.
通讯作者：
Morimoto, Bruce H.
影响因子：
3.3
作者：
Fiorenzato, Eleonora;Weis, Luca;Biundo, Roberta
通讯作者：
Biundo, Roberta
影响因子：
4
作者：
Kroonenberg, Pieter M;Oort, Frans J;Goetz, Christopher G
通讯作者：
Goetz, Christopher G
影响因子：
4.1
作者：
Bang, Jee;Lobach, Iryna V.;Boxer, Adam L.
通讯作者：
Boxer, Adam L.
影响因子：
11
作者：
Chiu, Wang Zheng;Kaat, L. D.;van Swieten, John C.
通讯作者：
van Swieten, John C.